trending Market Intelligence /marketintelligence/en/news-insights/trending/mob60kivjzkrdpi_fvgr4q2 content esgSubNav
In This List

GlycoMimetics plans common stock offering to fund trial of leukemia drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


GlycoMimetics plans common stock offering to fund trial of leukemia drug

GlycoMimetics Inc. plans to sell 4.5 million of its common shares in an underwritten public offering.

The company also plans to grant the underwriters an option to buy up to an additional 675,000 shares.

Maryland-based GlycoMimetics plans to use the net proceeds to complete its phase 3 clinical development program for GMI-1271 in patients with acute myeloid leukemia.

The company will also use the proceeds to fund the research and development of its other clinical-stage and preclinical product candidates, including drug discovery, and for working capital and other general corporate purposes.

Jefferies and Cowen are acting as joint book-running managers for the offering.